InnoCan Pharma:
Auf dem EPIDIOLEX®-Pfad zum Milliarden-Unternehmen.
Anzeige

FibroGen WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG

Kurs zur FIBROGEN Aktie
8,586 EUR
+6,04 %+0,489
26. May, 18:51:14 Uhr, Lang & Schwarz
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
Fee
Fee, 11. Mai 10:01
📌📌📌
Summer.76
Summer.76, 10. Mai 5:49
FibroGen GAAP EPS of -$0.68 beats by $0.24, revenue of $60.8M beats by $32.04M https://seekingalpha.com/news/3835294-fibrogen-gaap-eps-of-0_68-beats-0_24-revenue-of-60_8m-beats-32_04m • FibroGen press release (NASDAQ:FGEN): Q1 GAAP EPS of -$0.68 beats by $0.24. • Revenue of $60.8M (+58.2% Y/Y) beats by $32.04M. • Based on our latest forecast, we estimate a 2022 ending cash balance of $310-340 million.
Summer.76
Summer.76, 10. Mai 5:42
FibroGen Reports First Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/05/09/2439011/33525/en/FibroGen-Reports-First-Quarter-2022-Financial-Results.html • Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis • 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 • Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction
Summer.76
Summer.76, 28. Feb 22:21
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results https://www.globenewswire.com/news-release/2022/02/28/2393644/33525/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html • Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer • Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy • Total company revenue increased from $176.3 million in 2020 to $235.3 million in 2021
Summer.76
Summer.76, 20.12.2021 15:05
https://www.globenewswire.com/news-release/2021/12/20/2355186/33525/en/FibroGen-Exercises-Exclusive-License-Option-for-HiFiBiO-s-CCR8-Program.html
Summer.76
Summer.76, 10.11.2021 4:51
FibroGen Reports Third Quarter 2021 Financial Results https://finance.yahoo.com/news/fibrogen-reports-third-quarter-2021-210100110.html • Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a $120M milestone payment from Astellas • Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. • Total roxadustat net sales in China of $57.8 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca
s
schmutzli, 17.09.2021 21:25
was ist den hier los? nichts? sollte schon einmal steigen.
F
FutureFuel, 25.08.2021 20:42
https://www.globenewswire.com/news-release/2021/08/25/2286187/33525/en/FibroGen-Announces-Positive-Topline-Results-from-Phase-2-Clinical-Trial-of-Roxadustat-for-the-Treatment-of-Chemotherapy-Induced-Anemia.html
F
FutureFuel, 25.08.2021 20:42
FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial https://www.benzinga.com/general/biotech/21/08/22654151/fibrogens-roxadustat-aces-chemo-induced-anemia-trial
s
schmutzli, 20.08.2021 10:29
bin hier auch investiert und hatte schon meine Zweifel....
Kommentare
1 FIBROGEN Hauptdiskussion
Kursdetails
Geld (bid) 8,547 (3.088)
Brief (ask/offer) 8,625 (3.088)
Spread 0,904
Geh. Stück 0
Eröffnung 8,097
Vortag 8,097
Tageshoch 8,627
Tagestief 7,939
52W Hoch 26,230
52W Tief 7,406
Tagesvolumen
in EUR gehandelt 0 Stk
in USD gehandelt 567 Tsd. Stk
in CHF gehandelt 0 Stk
Gesamt 567 Tsd. Stk
Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Frankfurt 8,518 8,604 1653544836 08:00 7,979 EUR
Düsseldorf 8,502 8,611 1653580837 18:00 8,458 EUR
Stuttgart 8,518 8,604 1653573488 15:58 8,216 EUR
Nasdaq 9,170 9,180 1653582891 18:34 566.740 Stk 9,170 USD
AMEX 1653513600 25. May 100 Stk 8,640 USD
Tradegate 8,545 8,624 1653510419 25. May 8,107 EUR
Lang & Schwarz 8,547 8,625 1653583874 18:51 8,586 EUR
BX Swiss 8,030 8,091 1568217600 11. Sep 41,302 CHF
TTMzero RT 1653583764 18:49 8,585 EUR
TTMzero RT (USD) 1653583764 18:49 9,196 USD
ges. 566.840 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
732,9 Mio.
Anzahl der Aktien
93,3 Mio.
Grundlegende Daten zur FIBROGEN Aktie
Finanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
KUV - - - - - - -
Ergebnis je Aktie (bereinigt) - - - - - - -
Cashflow - - - - - - -
Eigenkapitalquote - - - - - - -
Verschuldungsgrad - - - - - - -
Eigenkapitalrendite - - - - - - -
Gesamtkapitalrendite - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Fundamentaldaten 2018 2019 2020 2021 2022e 2023e 2024e
KCV - - - - - - -
Dividendenrendite - - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - - -
Dividende je Aktie - - - - - - -
Bilanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
Netto-Provisionsüberschuss - - - - - - -
Umsatzerlöse - - - - - - -
Ergebnis vor Steuern - - - - - - -
Steuern - - - - - - -
Ausschüttungssumme - - - - - - -
Nettoverzinsung - - - - - - -
Zinsertrag - - - - - - -
Gesamtertrag - - - - - - -
BörsennewsApp
BörsennewsApp im Google Play Store
BörsennewsApp im Apple Store

© 2022 börsennews.de

Daten und Kurse:

TTMzero RealTime

SIX Financial Information SIX Financial Information

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.